12,202 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Acquired by Alpine Global Management LLC

Alpine Global Management LLC acquired a new stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 12,202 shares of the biopharmaceutical company’s stock, valued at approximately $37,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Natixis purchased a new position in Revance Therapeutics in the fourth quarter valued at $31,000. RPO LLC acquired a new position in Revance Therapeutics in the fourth quarter valued at approximately $55,000. KLP Kapitalforvaltning AS purchased a new position in Revance Therapeutics in the fourth quarter valued at approximately $74,000. Virtu Financial LLC acquired a new stake in Revance Therapeutics during the third quarter worth approximately $120,000. Finally, Wells Fargo & Company MN lifted its position in shares of Revance Therapeutics by 27.6% during the 4th quarter. Wells Fargo & Company MN now owns 49,373 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 10,675 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $3.65 on Wednesday. Revance Therapeutics, Inc. has a one year low of $2.30 and a one year high of $6.65. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The company has a 50-day simple moving average of $3.65 and a 200-day simple moving average of $3.89.

Analyst Upgrades and Downgrades

RVNC has been the topic of several research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. StockNews.com began coverage on Revance Therapeutics in a research report on Saturday. They set a “hold” rating on the stock. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.